Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) shares reached a new 52-week low on Wednesday . The stock traded as low as GBX 120 ($1.49) and last traded at GBX 120 ($1.49), with a volume of 38147 shares. The stock had previously closed at GBX 125 ($1.56).
Faron Pharmaceuticals Oy Stock Performance
The company has a debt-to-equity ratio of 121.51, a current ratio of 0.59 and a quick ratio of 1.09. The company’s fifty day simple moving average is GBX 165.15 and its two-hundred day simple moving average is GBX 247.54. The stock has a market cap of £82.57 million, a price-to-earnings ratio of -285.71 and a beta of -0.14.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- What to Know About Investing in Penny Stocks
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Are Penny Stocks a Good Fit for Your Portfolio?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
- The How And Why of Investing in Oil Stocks
- Abbott Laboratories Outlook is Healthy: Buy the Dip
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
